David Clem, Managing Partner, Lyme Properties
As the managing partner of Lyme Properties, David Clem oversees all aspects of the company's commercial real estate activities, including the acquisition, development, and leasing of first-quality life science and mixed-use properties. In Cambridge, Lyme has developed more than
1.5 million square feet of life science space, including 500 Kendall Street, the award-winning headquarters of Genzyme, and 200 Sidney Street, the headquarters of Vertex Pharmaceuticals, adjacent to MIT's University Park. Other projects include 270 Albany Street, 320 Bent, 301 Binney, and 675 West Kendall Street. In Boston, Lyme permitted, designed, and developed Center for Life Science Boston, a two-phase project comprising 1.2 million square feet that will have research facilities for Beth Israel Deaconess Medical Center, Dana Farber Cancer Institute, Children's Hospital Boston, and CBR Institute for Biomedical Research. Lyme has additional life science projects in New Haven, Connecticut, and Houston, Texas. All of Lyme's projects are in close proximity to premier educational, research, and medical centers.
Lyme strives to create buildings that set new standards for architecture, urban design, and environments for innovation. As a result, Lyme Properties has been the recipient of numerous awards including: U.S. Green Building Council LEED Platinum Rating; 2005 NAIOP Green Development Award Finalist; 2004 AIA Excellence in Sustainable Design Award; AIA COTE 2004 Top Ten Green Projects Award; and the EPA Phoenix Awards, Grand Prize Winner 2006 for Kendall Square, recognition for Excellence in Brownfield Redevelopment. The company is particularly noted for its involvement with and contribution to the "smart growth" and "green building" movements.